Chiesi and Gossamer Bio ink licensing deal on PAH candidate

Privately-held Italian drugmaker Chiesi Farmaceutici announced a deal with USA-based Gossamer Bio (Nasdaq: GOSS) for a global collaboration and license agreement to develop and commercialize the latter’s seralutinib. San Diego-based Gossamer’s shares rose 3% to $0.72 in pre-market trading on the news.

Chiesi said this global collaboration combines the strengths of both companies to support ongoing work in pulmonary arterial hypertension (PAH) and to accelerate development in pulmonary hypertension associated with interstitial lung disease (PH-ILD), with the aim of expanding the seralutinib franchise to reach more patients with pulmonary hypertension world-wide. Patients will benefit from both Chiesi’s expertise in global respiratory, rare disease, and inhaled drug development and commercialization and Gossamer’s world-class PAH and PH-ILD development and commercialization teams.

Chiesi is growing its presence in the USA, and the structure of this global collaboration agreement reflects this.